Kura Oncology (KURA) Current Assets (2010 - 2026)
Kura Oncology (KURA) reported Current Assets of $623.8 million for Q1 2026, down 13.87% year-over-year from $724.2 million in Q1 2025, and down 11.98% on a QoQ basis from $708.7 million in Q4 2025.
Kura Oncology (KURA) has 17 years of Current Assets data on file, last reported at $623.8 million in Q1 2026.
- Quarterly Current Assets fell 13.87% year-over-year to $623.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $623.8 million (down 13.87% YoY) and the FY2025 annual result came in at $708.7 million, down 4.86% from the prior year.
- Current Assets retreated to $623.8 million in Q1 2026 per KURA's latest filing, from $708.7 million in the prior quarter.
- Across five years, Current Assets topped out at $744.8 million in Q4 2024 and bottomed at $416.4 million in Q1 2023.
- The 5-year median for Current Assets is $487.0 million (2022), against an average of $541.6 million.
- The widest annual swing landed in 2022, when Current Assets declined 20.5%; it then soared 72.22% in 2024.
- Tracing KURA's Current Assets over 5 years: stood at $446.4 million in 2022, then retreated by 3.12% to $432.5 million in 2023, then jumped by 72.22% to $744.8 million in 2024, then declined by 4.86% to $708.7 million in 2025, then slipped by 11.98% to $623.8 million in 2026.
- Per Business Quant, the three latest KURA Current Assets figures stand at $623.8 million (Q1 2026), $708.7 million (Q4 2025), and $620.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 10.37 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.31 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.25 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 73.04 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 3.59 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 11.73 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.21 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.22 Bn |
| 10 | Kura Oncology | 801.92 Mn | 801.92 Mn | 18.00 Mn | 623.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 623.78 Mn |
| Dec 31, 2025 | 708.66 Mn |
| Sep 30, 2025 | 620.66 Mn |
| Jun 30, 2025 | 660.08 Mn |
| Mar 31, 2025 | 724.20 Mn |
| Dec 31, 2024 | 744.83 Mn |
| Sep 30, 2024 | 463.19 Mn |
| Jun 30, 2024 | 499.77 Mn |
| Mar 31, 2024 | 537.84 Mn |
| Dec 31, 2023 | 432.48 Mn |
| Sep 30, 2023 | 459.92 Mn |
| Jun 30, 2023 | 485.65 Mn |
| Mar 31, 2023 | 416.45 Mn |
| Dec 31, 2022 | 446.43 Mn |
| Sep 30, 2022 | 436.39 Mn |
| Jun 30, 2022 | 459.79 Mn |
| Mar 31, 2022 | 487.03 Mn |
| Dec 31, 2021 | 522.29 Mn |
| Sep 30, 2021 | 548.91 Mn |
| Jun 30, 2021 | 573.63 Mn |
| Mar 31, 2021 | 610.71 Mn |
| Dec 31, 2020 | 637.29 Mn |
| Sep 30, 2020 | 328.91 Mn |
| Jun 30, 2020 | 342.19 Mn |
| Mar 31, 2020 | 221.13 Mn |
| Dec 31, 2019 | 239.60 Mn |
| Sep 30, 2019 | 252.95 Mn |
| Jun 30, 2019 | 263.90 Mn |
| Mar 31, 2019 | 167.59 Mn |
| Dec 31, 2018 | 181.20 Mn |
| Sep 30, 2018 | 190.39 Mn |
| Jun 30, 2018 | 128.54 Mn |
| Mar 31, 2018 | 140.36 Mn |
| Dec 31, 2017 | 94.64 Mn |
| Sep 30, 2017 | 101.92 Mn |
| Jun 30, 2017 | 54.74 Mn |
| Mar 31, 2017 | 60.63 Mn |
| Dec 31, 2016 | 68.81 Mn |
| Sep 30, 2016 | 75.72 Mn |
| Jun 30, 2016 | 81.42 Mn |
| Mar 31, 2016 | 80.08 Mn |
| Dec 31, 2015 | 86.87 Mn |
| Sep 30, 2015 | 42.31 Mn |
| Jun 30, 2015 | 47.19 Mn |
| Mar 31, 2015 | 54.63 Mn |
| Dec 31, 2014 | 1.20 Mn |
| Mar 31, 2013 | 4,026.00 |
| Dec 31, 2012 | 8,302.00 |
| Sep 30, 2012 | 11,461.00 |
| Jun 30, 2012 | 15,731.00 |
| Mar 31, 2012 | 24,368.00 |
| Dec 31, 2011 | 6,720.00 |
| Sep 30, 2011 | 10,530.00 |
| Jun 30, 2011 | 15,505.00 |
| Mar 31, 2011 | 6,720.00 |
| Dec 31, 2010 | 29,398.00 |